RYZB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RYZB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. RayzeBio does not have enough data to calculate 10-Year RORE %.
The historical data trend for RayzeBio's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RayzeBio Annual Data | |||||||
Trend | Dec20 | Dec21 | Dec22 | ||||
10-Year RORE % | - | - | - |
RayzeBio Quarterly Data | ||||||||
Dec20 | Dec21 | Jun22 | Sep22 | Dec22 | Jun23 | Sep23 | ||
10-Year RORE % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, RayzeBio's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, RayzeBio's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where RayzeBio's 10-Year RORE % falls into.
RayzeBio's 10-Year RORE % for the quarter that ended in Sep. 2023 is calculated as:
10-Year RORE % | = | ( Most Recent EPS (Diluted) | - | First Period EPS (Diluted) ) | / | ( Cumulative EPS (Diluted) for 10-year | - | Cumulative Dividends per Share for 10-year ) |
= | ( | - | ) | / | ( | - | ) | |
= | / | |||||||
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2023 and 10-year before.
RayzeBio (NAS:RYZB) 10-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Thank you for viewing the detailed overview of RayzeBio's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Hauwermeiren Timothy Van | director | C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142 |
Viking Global Investors Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Maha Katabi | director | SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
Viking Global Opportunities Drawdown Gp Llc | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Viking Global Opportunities Drawdown Portfolio Gp Llc | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Arvind Kush | officer: Chief Financial Officer | C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121 |
Wellington Biomedical Innovation Master Investors (cayman) Ii L.p. | 10 percent owner | 280 CONGRESS STREET, BOSTON MA 02210 |
Versant Ventures Vii Gp-gp, Llc | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Versant Ventures Vii Gp, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Kenneth Song | director, officer: President and Chief Executive | C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121 |
Susan Moran | officer: Chief Medical Officer | 1232 RICHARDSON AVE, LOS ALTOS CA 94024 |
Venbio Global Strategic Gp Iii, L.p. | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Venbio Global Strategic Gp Iii, Ltd | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158 |
Venbio Global Strategic Fund Iii, L.p. | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Redmile Biopharma Investments Ii, L.p. | 10 percent owner | LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129 |
From GuruFocus
By Marketwired • 10-24-2023
By PRNewswire • 01-13-2024
By PRNewswire • 12-26-2023
By Business Wire • 09-19-2023
By Business Wire • 12-26-2023
By Marketwired • 11-01-2023
By Marketwired • 11-06-2023
By Business Wire • 12-31-2023
By Business Wire • 09-14-2023
By Marketwired • 10-18-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.